Literature DB >> 18387934

Newly approved does not always mean new and improved.

Geoffrey M Anderson1, David Juurlink, Allan S Detsky.   

Abstract

Mesh:

Year:  2008        PMID: 18387934     DOI: 10.1001/jama.299.13.1598

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  6 in total

1.  Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.

Authors:  Nicholas S Downing; Jenerius A Aminawung; Nilay D Shah; Harlan M Krumholz; Joseph S Ross
Journal:  JAMA       Date:  2014 Jan 22-29       Impact factor: 56.272

2.  Marketing, media, wishful thinking, and conflicts of interest: inflating the value of new medical technology.

Authors:  Richard A Deyo
Journal:  Perm J       Date:  2009

3.  Off-label prescribing: a call for heightened professional and government oversight.

Authors:  Rebecca Dresser; Joel Frader
Journal:  J Law Med Ethics       Date:  2009       Impact factor: 1.718

4.  Adoption of new drugs by physicians: a survival analysis.

Authors:  Francisco Javier Garjón; Ana Azparren; Iván Vergara; Borja Azaola; Jose Ramón Loayssa
Journal:  BMC Health Serv Res       Date:  2012-03-08       Impact factor: 2.655

Review 5.  Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review.

Authors:  Alison M Pease; Harlan M Krumholz; Nicholas S Downing; Jenerius A Aminawung; Nilay D Shah; Joseph S Ross
Journal:  BMJ       Date:  2017-05-03

6.  Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study.

Authors:  Constance X Zou; Jessica E Becker; Adam T Phillips; James M Garritano; Harlan M Krumholz; Jennifer E Miller; Joseph S Ross
Journal:  Trials       Date:  2018-10-23       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.